AUS
NZ
UK
CA
USA
IND
Highlights:
- New Funding Needed: Oxford BioDynamics announced that it requires additional funding by Q1 2025 to maintain operations.
- Cost-Cutting Initiatives: Senior staff will receive 25% of their pay in shares as part of efforts to conserve cash.
- Focus on PSE Test Sales: The company is shifting resources to boost sales of its PSE prostate screening tests, which grew by 86% in the second half of the year.
Oxford BioDynamics PLC (LSE:OBD), a precision medicine test developer, has seen its shares plummet by over 37% as the company warned that new funding would be required by early next year. The significant drop in share price comes as the company outlines efforts to cut costs, raise capital, and explore restructuring options to secure its financial future.
Cost-Cutting Measures and Funding Needs
Oxford BioDynamics announced a series of measures aimed at conserving cash in light of its high burn rate and limited access to capital in the UK market. Among these initiatives is a plan for senior staff to receive 25% of their pay through newly issued shares, which will help reduce cash outflow. The company also revealed that it is reviewing various funding options, including selling company assets or potentially spinning off its U.S. wing into a separate business.
The company emphasized the urgency of the situation, stating that additional funds would be required by the first quarter of 2025. "The board and management recognize the need to maximize the company's cash runway," Oxford BioDynamics said in its announcement.
Strategic Focus on Prostate Screening Test Sales
Amid its financial challenges, Oxford BioDynamics highlighted a strategic shift in focus towards growing sales of its PSE prostate screening tests. Over the second half of the year, sales of these tests grew by 86%, reaching 483 units. The company is reallocating resources to capitalize on this growth as part of its broader strategy to enhance revenue generation and reduce dependency on external funding.
Future Prospects and Market Reaction
The announcement triggered a sharp sell-off in Oxford BioDynamics' shares, which fell by 37.2% to 2.30p on Monday. Investors reacted to the company's acknowledgment of its financial challenges, particularly its reliance on new funding to maintain operations beyond early 2025. The company’s efforts to cut costs, explore new funding avenues, and refocus on its core product offerings will be closely watched in the coming months as it seeks to stabilize its financial position.
